COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00355251
Recruitment Status : Terminated (On the basis of published results of SMART study, it has been observed that the results are worse in patients who have interrupted their treatments.)
First Posted : July 21, 2006
Last Update Posted : March 20, 2014
Fundacio Lluita Contra la SIDA
Information provided by:
Germans Trias i Pujol Hospital

Brief Summary:
To determine the influence of atorvastatin on plasma viral replication when the latter is given before and during highly active anti-retroviral therapy (HAART) in patients with HIV infection and viral suppression.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Atorvastatin 40 mg/Atorvastatin 80 mg Phase 4

Detailed Description:

Recently, the inhibitory effect of the statins on the replication of the human immunodeficiency virus Type 1 (HIV-1) through two independent mechanisms of action has been described: the blockade of Rho guanosine triphosphatase that intervenes in the entry and exit of the virus and the blockade of the interaction between LFA-1 (leukocyte function antigen 1) and its ICAM 1 ligand (intercellular adhesion molecule 1) that intervenes in the process through which the virus binds to the target cell.

These initial data have led to the study of the effect of atorvastatin on the plasma replication of HIV in HIV+ patients that interrupt antiretroviral therapy (Ator Study 3) developed in our unit. The data of this study indicate that baseline plasma cholesterol determines viral load rebound on interrupting antiretroviral treatment. However, the introduction of atorvastatin on the day of interruption provided no virological or immunological benefit in comparison with an interruption of antiretrovirals without statins. This may be due to the fact that the potent inhibitory effect of atorvastatin is unable to compensate their activating effect on the production of HIV also described in our study.

Overall, our results pose a possible usefulness of atorvastatin in the control of viral replication if given before the interruption of antiretroviral therapy due to:

  • Their capacity to reduce serum cholesterol at the time of interruption and consequently the cholesterol of the cell membrane.
  • Their potent capacity to purge the HIV reservoir

Therefore, in this study we aim to investigate the impact of atorvastatin on viral replication when it is given 8 weeks before the interruption of the antiretroviral treatment and determine whether this impact is due to the reduction in serum and/or membrane cholesterol, or whether, on the other hand, there is a contribution by atorvastatin's capacity to induce the expression of viral products.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of the Influence of Atorvastatin in Plasma Viral Replication Given Prior to Antiretroviral Treatment Interruption in Patients With HIV-1 Infection and Viral Suppression.
Study Start Date : July 2006
Actual Primary Completion Date : December 2006
Actual Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: A
4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
Drug: Atorvastatin 40 mg/Atorvastatin 80 mg
Atorvastatin 40 mg/80 mg

No Intervention: B
4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento

Primary Outcome Measures :
  1. The primary endpoint is viral load (HIV RNA) in plasma. [ Time Frame: at 12 and 24 weeks ]

Secondary Outcome Measures :
  1. CD4 and CD8, absolute value, percentage and activation. [ Time Frame: during the 32 weeks of follow-up ]
  2. Total cholesterol, HDL and LDL in serum. [ Time Frame: during the 32 weeks of follow-up ]
  3. Cholesterol in cell membrane. [ Time Frame: during the 32 weeks of follow-up ]
  4. Symptoms reported by the patient following the interruption of the HAART therapy or signs detected by the clinician (classification according to the WHO), mainly those which may indicate acute antiretroviral symptoms. [ Time Frame: during the 32 weeks of follow-up ]
  5. Creatinine, urea, creatine kinase (CK), hepatic tests, (AST, ALT, GGT) [ Time Frame: during the 32 weeks of follow-up ]
  6. Proviral load. [ Time Frame: during the 32 weeks of follow-up ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age >= 18 years.
  2. Patients with chronic infection by HIV-1 in stable highly active antiretroviral treatment (>= 6 months).
  3. Undetectable plasma viral load (<50 copies/mL) in the last 3 determinations over the last 6 months.
  4. CD4 > 500 cells/mm>=3 in the last two determinations.
  5. Documented prior viral load at some time of >15,000 copies/mL.
  6. Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study.
  7. Signature of the informed consent

Exclusion Criteria:

  1. CD4 nadir <= 200 cells/mm3.
  2. Background of infections or other AIDS-defining pathology.
  3. Intercurrent infections in the last 6 months.
  4. Creatine kinase (CK) >= 500 U/L.
  5. AST or ALT >= 3 times higher than the upper limit of normality.
  6. Treatment with others statins, fibrates, macrolides or fluconazole in the last 3 months.
  7. Pregnancy or breastfeeding
  8. Patients participating in another clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00355251

Layout table for location information
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain, 08916
Sponsors and Collaborators
Germans Trias i Pujol Hospital
Fundacio Lluita Contra la SIDA
Layout table for investigator information
Principal Investigator: Bonaventura Clotet, MD,PhD LLuita contra la Sida Foundation-HIV Unit
Layout table for additonal information
Responsible Party: Fundació Lluita contra la Sida Identifier: NCT00355251    
Other Study ID Numbers: PRE-ATOR
First Posted: July 21, 2006    Key Record Dates
Last Update Posted: March 20, 2014
Last Verified: February 2014
Keywords provided by Germans Trias i Pujol Hospital:
Viral replication
plasma cholesterol
Cell membrane cholesterol
Additional relevant MeSH terms:
Layout table for MeSH terms
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors